EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma



RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma



Molecular Cancer Research 11(7): 748-758



Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor that is methylated in many human cancers, including hepatocellular carcinoma (HCC). RASSF1A has been shown to suppress tumors via activation of the Hippo tumor suppressor pathway, including mammalian STE20-like kinase (MST). Amphiregulin (AREG), a target gene for Yes-associated protein (YAP), is a known oncogenic component of the Hippo pathway; however, the tumor-suppressive effect of RASSF1A on AREG in regard to regulation of the Hippo pathway remains unclear in HCC. Overexpression of RASSF1A in HCC cells, which lack functional RASSF1A, significantly inhibited cell proliferation and induced apoptosis by activating the Hippo pathway. Consequently, overexpression of RASSF1A inhibited the oncogenic functions of YAP, leading to a significant reduction in AREG secretion via regulation of the Hippo pathway. In human specimens, greater expression of RASSF1A was observed in chronic hepatitis/cirrhosis than in HCC, whereas expression of YAP and AREG was higher in 81% and 86% of HCC than in corresponding chronic hepatitis/cirrhosis, respectively. Furthermore, RASSF1A protein gradually decreased as multistep hepatocarcinogenesis progressed from chronic hepatitis/cirrhosis dysplastic nodules toward HCC, whereas the protein expression of YAP and AREG gradually increased. These findings provide mechanistic insight into the regulation of YAP and AREG by RASSF1A in human multistep hepatocarcinogenesis.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333497

Download citation: RISBibTeXText

PMID: 23594797

DOI: 10.1158/1541-7786.MCR-12-0665



Related references

RASSF1A Downregulates AREG by Activation of Hippo Pathway. 2013

TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma. Oncotarget 8(9): 15689-15703, 2017

The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action. Cancer Letters 400: 175-182, 2017

Hippo tumor supressor pathway: novel implications for the treatment of hepatocellular carcinoma. Gastroenterology 139(2): 692-694, 2010

Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. Clinical Cancer Research 22(5): 1256-1264, 2016

Decursin inhibits the growth of HepG2 hepatocellular carcinoma cells via Hippo/YAP signaling pathway. PhytoTherapy Research, 2018

TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation. Molecular Cell 63(1): 156-166, 2017

Histone acetylation-mediated regulation of the Hippo pathway. Plos One 8(5): E62478-E62478, 2013

High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. International Journal of Molecular Sciences 20(3), 2019

Salvador protein is a tumor suppressor effector of RASSF1A with hippo pathway-independent functions. Journal of Biological Chemistry 286(21): 18483-18491, 2011

Nanocurcumin-Mediated Down-Regulation of Telomerase Via Stimulating TGFβ1 Signaling Pathway in Hepatocellular Carcinoma Cells. Iranian Biomedical Journal 22(3): 171-179, 2017

Protein kinase A-mediated phosphorylation of the RASSF1A tumour suppressor at Serine 203 and regulation of RASSF1A function. European Journal of Cancer 46(16): 2986-2995, 2011

Regulation of demethylation and re-expression of RASSF1A gene in hepatocellular carcinoma cell lines treated with NCTD in vitro. Journal of Cancer Research and Therapeutics 11(4): 818-822, 2016

A genetic variant in large tumor suppressor kinase 2 of Hippo signaling pathway contributes to prognosis of hepatocellular carcinoma. Oncotargets and Therapy 9: 1945-1951, 2016

Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. Molecular and Cellular Biochemistry: -, 2018